Document is current

Article History

Received: 7 June 2025

Accepted: 13 October 2025

First Online: 27 October 2025

Declarations

:

: HJA reports consulting fees (speaker, Advisory Board, and Data Safety Board honoraria) from Boehringer Ingelheim, Roche, and Novo Nordisk. FJAM reports consulting fees from Stryker, MicroVention, and Balt. VP reports payment or honoraria for lectures, presentations, or educational events from Boehringer Ingelheim, Daiichi Sankyo, AstraZeneca, and Bristol Myers Squibb, and support for attending meetings or travel from NoNo (travel reimbursement). PM reports consulting fees from Medtronic and steering committee fees from Penumbra, all paid to his institution. TGJ is advisor and investor for Anaconda, Route92, Viz.ai, FreeOx, Blockade Medical, and Methinks. He received personal fees in his role on the data and safety monitoring board (DSMB) and steering committee from Cerenovus and on the screening committee for Contego Medical. He received stock as an advisory board member for Corindus. He received grant support for Medtronic and from Stryker Neurovascular in his capacity as principal investigator for DAWN and AURORA. WHvZ reports speaker fees from Stryker, Cerenovus, MicroVention, Medtronic, and Nicolab, and consulting fees from Philips, all paid to institution; chaired the DSMBs of WeTrust (Philips) and ANAIS (Anaconda), all paid to his institution. WHvZ chaired the DSMB of InExtremis (CHU Montpellier, Montpellier, France), for which no payment was received. RGN reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron; and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, CrestecBio, Euphrates Vascular, Vesalio, Viz.ai, RapidPulse, and Perfuze. RGN is one of the Principal Investigators of the Endovascular Therapy for Low NIHSS Ischemic Strokes (ENDOLOW) trial. Funding for this project is provided by Cerenovus. RGN is the Principal Investigator of the Combined Thrombectomy for Distal Medium Vessel Occlusion Stroke (DUSK) trial. Funding for this project is provided by Stryker Neurovascular. RGN is an investor in Viz.ai, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, Tulavi Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis.ai, and Viseon. The rest of the coauthors have nothing to declare.

: The ATTENTION, BEST, BAOCHE, and BASICS trial had approval by each local medical ethical committee at the participating centers.

: For this type of study, consent for publication is not required.

: Written informed consent was obtained from all subjects before the study.